UP
UP0.F Ultragenyx Pharmaceutical Inc
- Market cap
- EUR 1.51B
- P/E
- -
- P/B
- 19.57x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is UP0.F undervalued?
Graham numberThe Graham number of Ultragenyx Pharmaceutical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ultragenyx Pharmaceutical Inc fundamental analysis
No fundamental analysis for Ultragenyx Pharmaceutical Inc yet.
Ultragenyx Pharmaceutical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced …
Full company profileUltragenyx Pharmaceutical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ultragenyx Pharmaceutical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 133K | 2.61M | 51.5M | 104M | 271M | 351M | 363M | 434M | 560M | 673M | 697M |
| Gross Profit | -183M | 2.61M | 50.3M | 94.7M | 265M | 335M | 335M | 389M | 483M | 564M | 569M |
| Operating Income | -248M | -329M | -371M | -424M | -330M | -382M | -649M | -569M | -536M | -535M | -472M |
| EBITDA | - | -323M | -352M | -390M | -140M | -424M | -659M | -517M | -468M | -474M | -419M |
| Net Income | -246M | -302M | -198M | -403M | -187M | -454M | -707M | -607M | -569M | -575M | -527M |
| EPS | - | -6.84 | -3.89 | -6.96 | -2.79 | -6.66 | -10 | -7.37 | -6.15 | -5.96 | -5.17 |
| Balance Sheet | |||||||||||
| Total Assets | 541M | 491M | 720M | 1.14B | 1.76B | 1.52B | 1.55B | 1.49B | 1.50B | 1.53B | 1.19B |
| Total Liabilities | 66.7M | 107M | 111M | 482M | 605M | 600M | 1.19B | 1.22B | 1.24B | 1.61B | 1.56B |
| Shareholders' Equity | 474M | 383M | 609M | 654M | 1.15B | 923M | 352M | 275M | 255M | -80.0M | -376M |
| Cash & Short-term Investments | 161M | 100M | 113M | 434M | 714M | 308M | 133M | 214M | 174M | 421M | 150M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -161M | -254M | -291M | -345M | -132M | -339M | -380M | -481M | -414M | -466M | -449M |
| Capital Expenditure | 10.2M | 2.79M | 4.08M | 24.8M | 43.9M | 73.1M | 116M | 72.1M | 20.0M | 21.0M | 12.0M |
| Free Cash Flow | - | -257M | -295M | -370M | -176M | -412M | -527M | -553M | -434M | -487M | -461M |
| Ratios | |||||||||||
| ROE | -51.9% | -78.8% | -32.5% | -61.6% | -16.2% | -49.2% | -200.7% | -220.4% | -222.9% | - | - |
| ROA | -45.5% | -61.6% | -27.5% | -35.5% | -10.6% | -29.8% | -45.8% | -40.7% | -37.8% | -37.5% | -44.4% |
| Net Profit Margin | -184,867.7% | -11,567.3% | -383.7% | -388.3% | -68.8% | -129.2% | -194.7% | -139.9% | -101.6% | -85.4% | -75.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Ultragenyx Pharmaceutical Inc dividends
Ultragenyx Pharmaceutical Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:3.1345 on Jan 17, 2014.
Who owns Ultragenyx Pharmaceutical Inc
- Insiders 3.32%
- Institutions 96.68%
- Public & others 0.00%
- Shares outstanding 102M
- Free float 77.4M
Ultragenyx Pharmaceutical Inc company profile
- Company name
- Ultragenyx Pharmaceutical Inc
- Ticker
- UP0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,371
- Fiscal year end
- December
- Address
- 60 Leveroni Court, Novato, CA, United States, 94949
- Phone
- 415 483 8800
- Website
- ultragenyx.com
About Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Ultragenyx Pharmaceutical Inc management
10- Dr. Emil D. Kakkis M.D., Ph.D.Founder, President, CEO & Director · born 1960
- Mr. Howard HornExecutive VP of Corporate Strategy & CFO · born 1979
- Ms. Karah Herdman Parschauer J.D.Chief Legal Officer & Executive VP of Corporate Affairs · born 1978
- Mr. Erik Harris M.B.A.Executive VP & Chief Commercial Officer · born 1970
- Dr. Eric Crombez M.D.Chief Medical Officer & Executive VP · born 1973
- Mr. Theodore A. HuizengaSenior VP, Corporate Controller & Principal Accounting Officer · born 1971
- Mr. Ernie W. MeyerChief Human Resources Officer & Executive VP · born 1965
- Mr. Vimal SrivastavaSenior Vice President of Business Development & Alliance Management · born 1965
- Mr. Dennis Karl HuangChief Technical Operations Officer and Executive VP of Gene Therapy Operations
- Mr. John Richard Pinion IIChief Quality Operations Officer & Executive VP of Translational Sciences · born 1966